Related Experiment Video
Updated: Jun 11, 2026
Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules
Published on: July 25, 2013
Rational design, synthesis, and biophysical characterization of a peptidic MDM2-MDM4 interaction inhibitor
Marco Ballarotto1, Elisa Bianconi1, Sonia Valentini2
1Dipartimento di Scienze Farmaceutiche, Università degli Studi di Perugia, Via del Liceo, 1, 06123 Perugia, Italy.
Abstract:
In recent years, the restoration of p53 physiological functions has become an attractive therapeutic approach to develop novel and efficacious cancer therapies. Among other mechanisms, the oncosuppressor protein p53 is functionally regulated by MDM2 through its E3 ligase function. MDM2 promotes p53 ubiquitination and degradation following homodimerization or heterodimerization with MDM4. Recently, we discovered Pep3 (1, Pellegrino et al., 2015), a novel peptidic inhibitor of MDM2 dimerization able to restore p53 oncosuppressive functions both in vitro and in vivo. In this work, we were able to identify the key interactions between peptide 1 and MDM2 RING domain and to design peptide 2, a truncated version of 1 that is still able to bind MDM2. Integrating both computational and biophysical techniques, we show that peptide 2 maintains the conserved peptide 1-MDM2 interactions and is still able to bind to full-length MDM2.
Insights
Restoring tumor suppressor p53 function is a promising cancer therapy. A new peptide, peptide 2, inhibits MDM2 dimerization, a key step in p53 degradation, thereby restoring p53
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Restoring p53 tumor suppressor activity is a key strategy for novel cancer therapies.
- The E3 ligase MDM2 regulates p53 stability by promoting its ubiquitination and degradation.
- MDM2-MDM4 interactions are crucial for MDM2's ligase activity and p53 regulation.
Purpose of the Study:
- To identify key interactions between a previously discovered peptide inhibitor (Pep1) and the MDM2 RING domain.
- To design and characterize a truncated version of Pep1 (peptide 2) that retains MDM2 binding and inhibitory activity.
- To validate peptide 2 as a potential therapeutic agent for restoring p53 function in cancer.
Main Methods:
- Computational modeling to analyze peptide-MDM2 interactions.
- Biophysical techniques to assess peptide binding to MDM2.
- In vitro and in vivo studies to evaluate the restoration of p53 functions.
Main Results:
- Identified critical interactions between peptide 1 and the MDM2 RING domain.
- Designed peptide 2, a truncated analog of peptide 1, which maintains essential binding interactions.
- Demonstrated that peptide 2 binds to full-length MDM2, preserving the inhibitory mechanism of peptide 1.
Conclusions:
- Peptide 2 is a potent inhibitor of MDM2 dimerization, effectively restoring p53 tumor suppressor activity.
- The truncated peptide 2 represents a promising therapeutic candidate for cancer treatment by reactivating p53.
- Further development of peptide 2 could lead to novel, effective cancer therapies targeting the MDM2-p53 pathway.
More Related Videos
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
05:17Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
Published on: February 9, 2021
